Stressgen Biotechnologies Inc., of Victoria, British Columbia, said there was were some errors in a news item that came from an Antigenics Inc. news release in the Nov. 15, 2000, issue of BioWorld Today. Stressgen said a ruling at a hearing in Munich, Germany, related to a patent issued to the Whitehead Institute and exclusively licensed to Stressgen, not a patent issued to Stressgen. The company said the ruling has no impact on its core intellectual property filings related to stress protein fusion technology, including its HspE7 product. Stressgen added that it has more than 70 applications pending or granted in the heat shock protein area, including ones covering immunotherapeutics, countering an Antigenics claim.
Editor's Note: The changes will be made Thursday on BioWorld Online.